SESSION 1. Aldosterone Receptor antagonists clinical interest: Beyond the “Aldosterone escape” concept Allan STRUTHERS Learn more
SESSION 1. Questions and Answers I ADRIAN BOSWOOD, Allan STRUTHERS, CLARKE ATKINS, JONATHAN ELLIOTT Learn more
SESSION 2. Treatment of preserved cardiac function heart failure with an Aldosterone antagonist: the NHLBI TOPCAT Trial BERTRAM PITT Learn more
SESSION 2. The DELAY STUDY (DElay of Appearance of sYmptoms of canine degenerative mitral valve disease treated with Spironolactone and Benazepril) MICHELE BORGARELLI Learn more
SESSION 2. Questions and Answers II BERTRAM PITT, FAIEZ ZANNAD, Jens HÄGGSTRÖM, MICHELE BORGARELLI Learn more
SESSION 3. Biomarkers: what are the practical uses and what canbe expected in the coming years? Jens HÄGGSTRÖM Learn more
SESSION 4. A rock and a hard place: cardiorenal syndrome in clinical canine veterinary patients Rebecca STEPIEN Learn more
SESSION 4. Mineralocorticoid receptor antogonists: New therapeutic opportunities in chronic kidney diseases FRÉDÉRIC JAISSER Learn more
SESSION 4. Questions and Answers IV CLARKE ATKINS, Claudio RONCO, FRÉDÉRIC JAISSER, Rebecca STEPIEN Learn more
